Physician profile
Sean Streff
NPI 1912490665
$7,683.62
in general payments reported to CMS, 2019-2025
20 companies · $982 in 2025
The $982 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,918 · 2020: $197 · 2021: $292 · 2022: $1,852 · 2023: $952 · 2024: $1,491 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,925 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $400 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,924.64 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $400.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,780.27 | 2019-2025 | Tryptyr, Total30, Rocklatan |
| Biotissue Holdings INC. | $1,556.44 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $1,132.56 | 2023-2025 | Xiidra, Miebo, Infuse |
| Mallinckrodt Hospital Products INC. | $470.28 | 2023-2025 | Acthar |
| Johnson & Johnson Vision Care, INC. | $421.21 | 2019-2025 | Acuvue |
| Dompe US, INC. | $402.36 | 2022-2025 | Oxervate |
| Horizon Therapeutics Plc | $352.81 | 2021-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $345.53 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $250.60 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $225.40 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $176.82 | 2019 | |
| Oyster Point Pharma, INC. | $168.36 | 2023-2024 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $105.40 | 2019-2021 | |
| Harrow Eye, LLC | $78.31 | 2024-2025 | Vevye |
| Rxsight INC | $55.56 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $53.44 | 2022-2023 | Lumigan |
| Kala Pharmaceuticals, INC. | $36.80 | 2021 | |
| Glaukos Corporation | $31.91 | 2019 | |
| Amgen INC. | $23.49 | 2024 | Tepezza |
| Thea Pharma INC. | $16.07 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Streff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.